重组人血管内皮抑素不同给药途径联合吉西他滨对进展期卵巢癌疗效影响  

Effects of Different Routes of Administration of Recombinant Human Endostatin Combined with Gemcitabine on Advanced Ovarian Cancer

作　　者：关鑫[1] 刁海丹[1] 

机构地区：[1]辽宁大连市第三人民医院妇科,大连116033

出　　处：《航空航天医学杂志》2017年第11期1314-1316,共3页Journal of Aerospace medicine

摘　　要：目的探究重组人血管内皮抑素(恩度)不同的给药方式联合吉西他滨对进展期卵巢癌患者的疗效及不良反应的情况。方法选取2014年6月-2016年6月收治的进展期卵巢癌患者,在同时联合吉西他滨的基础上,根据重组人血管内皮抑素的不同给药方式分为观察组(持续静脉泵给药)和对照组(静脉滴注给药)。记录患者的治疗情况,血清VEGF水平及不良反应的发生情况。结果治疗2个疗程后,治疗有效率及疾病控制率在两组间的比较无显著差异,4个疗程后,观察组的治疗有效率及疾病控制率均显著高于对照组(P<0.05);VEGF水平的变化:治疗前,两组患者的VEGF水平无显著差异,治疗2个疗程后,观察组的VEGF水平较对照组下降明显,4个疗程后结果同,差异均具有统计学意义(P<0.05);不良反应的发生情况:心电图变化及骨髓抑制在观察组中的发生率明显低于对照组(P<0.05),而脱发、肌肉酸痛及恶心呕吐等不良反应在两组中的发生率无显著差异(P>0.05)。结论应用持续静脉泵给药方式对重组人血管内皮抑素进行给药并联合吉西他滨的疗效更好,VEGF水平下降明显且无显著的不良反应。Objective To observe the efficacy of intravenous infusion and pump of rh-endostatin injection（ Endostar） combined with Gemcitabine on patients with advanced ovarian cancer.Methods Patients with advanced ovarian cancer were selected in our hospital from June 2014 to June 2016.The patients were divided into observation group and control group according to administration of Endostar.VEGF levels and tumor size were observed to estimate the efficacy and safety.Results After 2 cycles of treatment,there was no significant difference in the effective rate and disease control rate between the two groups.After 4 cycles of the treatment,the effective rate and disease control rate of the observation group were significantly higher than those of the control group; After 2 courses of treatment,the level of VEGF in the observation group was significantly lower and the results of the course of the 4 courses were the same; EKG changes and bone marrow in the observation group were significantly lower.Conclusions The effect of continuous intravenous infusion in the treatment of recombinant human endostatin is better,the level of VEGF decreased significantly and no significant adverse reactions are observed.

关 键 词：给药方式 吉西他滨 卵巢癌 

分 类 号：R737.31[医药卫生—肿瘤]